Eagle Health Investments’s Kymera Therapeutics KYMR Stock Holding History

Eagle Health Investments’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.1M	Buy	166,148 +20,332	+14%	+$1.75M	3.16%	14
2026 Q1	$12.1M	Buy	145,816 +9,516	+7%	+$754K	2.12%	17
2025 Q4	$10.6M	Buy	+136,300	New	+$9.2M	2.33%	14
2022 Q2	–	Sell	-37,000	Closed	-$1.57M	–	30
2022 Q1	$1.57M	Hold	37,000	–	–	0.39%	24
2021 Q4	$2.35M	Hold	37,000	–	–	0.57%	23
2021 Q3	$2.17M	Hold	37,000	–	–	0.69%	22
2021 Q2	$1.79M	Buy	+37,000	New	+$1.61M	0.62%	24

Other funds holding KYMR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Eagle Health Investments's KYMR Position: Q2 2026 in Review

Eagle Health Investments increased its Kymera Therapeutics (KYMR) stake by 14% in Q2 2026, buying an estimated $1.75M and bringing the position to 166,148 shares worth $19.1M. The position accounts for 3.16% of the portfolio, ranked #14.

Eagle Health Investments first reported a position in KYMR in Q2 2021 and has held it in 7 quarters since. 100 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Eagle Health Investments held 166,148 shares of Kymera Therapeutics worth $19.1M as of Q2 2026.
Eagle Health Investments bought 20,332 Kymera Therapeutics shares in Q2 2026, an estimated $1.75M.
Kymera Therapeutics made up 3.16% of Eagle Health Investments's portfolio in Q2 2026, its #14 holding.
Eagle Health Investments first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 7 quarters since.
100 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Eagle Health Investments's 13F filing for Q2 2026, filed 10 Aug 2026.